Loading...
XKRX293480
Market cap129mUSD
Jan 08, Last price  
10,880.00KRW
1D
-0.64%
1Q
-2.86%
IPO
-61.02%
Name

Hana Pharm Co Ltd

Chart & Performance

D1W1MN
XKRX:293480 chart
P/E
8.43
P/S
0.84
EPS
1,290.95
Div Yield, %
4.69%
Shrs. gr., 5y
3.48%
Rev. gr., 5y
7.99%
Revenues
224.46b
+6.46%
108,942,199,007124,534,998,810139,331,265,580152,832,773,570166,346,999,040177,305,504,030196,406,570,950210,844,992,160224,456,850,812
Net income
22.33b
-8.12%
4,911,355,98417,430,848,40024,304,637,75026,169,074,15028,303,724,60014,892,864,95028,013,835,90024,307,179,31022,332,770,010
CFO
18.40b
-40.41%
7,839,446,47812,463,934,80025,380,166,50027,586,563,92031,717,117,21015,579,887,70025,655,058,07030,883,523,26018,403,706,504
Dividend
Dec 28, 2022510 KRW/sh
Earnings
Mar 13, 2025

Profile

Hana Pharm Co., Ltd. develops and provides various pharmaceutical products in South Korea and internationally. It offers anesthetics, narcotic analgesics, antiemetics, muscle relaxants, cardiovascular and endocrine system, gastrointestinal system, respiratory system, antibiotics, dermatology, urinology, osteoporosis, and central nervous system products, as well as analgesics, antipyretics, and anti-inflammatory drugs. The company was founded in 1958 and is headquartered in Seoul, South Korea.
URL
http://www.hanaph.co.kr/
IPO date
Oct 02, 2018
Employees
Domiciled in
KR
Incorporated in
KR

Valuation

Title
KRW in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFY
2023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑12
Income
Revenues
224,456,851
6.46%
210,844,992
7.35%
Cost of revenue
147,530,477
132,509,026
Unusual Expense (Income)
NOPBT
76,926,374
78,335,966
NOPBT Margin
34.27%
37.15%
Operating Taxes
5,574,186
6,411,172
Tax Rate
7.25%
8.18%
NOPAT
71,352,188
71,924,795
Net income
22,332,770
-8.12%
24,307,179
-13.23%
Dividends
(8,822,738)
(8,822,738)
Dividend yield
3.66%
2.79%
Proceeds from repurchase of equity
BB yield
Debt
Debt current
24,934,219
11,967,376
Long-term debt
4,693,911
25,787,446
Deferred revenue
74,000
76,364
Other long-term liabilities
12,602,065
10,066,815
Net debt
(45,493,818)
(4,632,038)
Cash flow
Cash from operating activities
18,403,707
30,883,523
CAPEX
(14,683,402)
(35,771,449)
Cash from investing activities
(11,894,229)
(36,507,579)
Cash from financing activities
(17,635,257)
11,556,956
FCF
50,498,170
41,536,037
Balance
Cash
6,158,791
17,582,283
Long term investments
68,963,158
24,804,576
Excess cash
63,899,106
31,844,610
Stockholders' equity
184,443,241
179,039,475
Invested Capital
253,481,338
274,488,437
ROIC
27.03%
27.03%
ROCE
24.24%
25.52%
EV
Common stock shares outstanding
17,299
17,299
Price
13,950.00
-23.56%
18,250.00
-9.43%
Market cap
241,327,830
-23.56%
315,715,620
-6.09%
EV
195,834,012
311,083,582
EBITDA
84,506,223
84,830,809
EV/EBITDA
2.32
3.67
Interest
600
585,668
Interest/NOPBT
0.00%
0.75%